Abstract:Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD), the absence of approved therapies is striking. Although the mainstay of treatment of NAFLD is weight loss, it is hard to maintain, prompting the need for pharmacotherapy as well. A greater understanding of disease pathogenesis in recent years was followed by development of new classes of medications, as well as potential repurposing of currently available agents. NAFLD therapies target four main pathways. The dominant approach is targeting hepatic fat accumulation and the resultant metabolic stress. Medications in this group include peroxisome proliferator-activator receptor agonists (eg, pioglitazone, elafibranor, saroglitazar), medications targeting the bile acid-farnesoid X receptor axis (obeticholic acid), inhibitors of de novo lipogenesis (aramchol, NDI-010976), incretins (liraglutide) and fibroblast growth factor (FGF)-21 or FGF-19 analogues. A second approach is targeting the oxidative stress, inflammation and injury that follow the metabolic stress. Medications from this group include antioxidants (vitamin E), medications with a target in the tumour necrosis factor α pathway (emricasan, pentoxifylline) and immune modulators (amlexanox, cenicriviroc). A third group has a target in the gut, including antiobesity agents such as orlistat or gut microbiome modulators (IMM-124e, faecal microbial transplant, solithromycin). Finally, as the ongoing injury leads to fibrosis, the harbinger of liver-related morbidity and mortality, antifibrotics (simtuzumab and GR-MD-02) will be an important element of therapy. It is very likely that in the next few years several medications will be available to clinicians treating patients with NAFLD across the entire spectrum of disease.

Real-world data support the use of essential phospholipids in non-alcoholic fatty liver disease

Meta-analysis and narrative review confirm the benefit of essential phospholipids in non-alcoholic fatty liver disease

Real-world evidence for beneficial effects of essential phospholipids in patients with non-alcoholic fatty liver disease

Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease

Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics

Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities

Phospholipids in non-alcoholic fatty liver disease

Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates

Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

Advancements in Non-Alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Treatment: From Lifestyle Interventions to Novel Therapies

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Current treatment of non‐alcoholic fatty liver disease

Non‐Alcoholic Fatty Liver Disease

[What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?]

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD

The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease

Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment

Phloroglucinol Strengthens the Antioxidant Barrier and Reduces Oxidative/Nitrosative Stress in Nonalcoholic Fatty Liver Disease (NAFLD)

Natural compounds proposed for the management of non-alcoholic fatty liver disease